Stocks Health care AXSM
NASDAQ · Health careAxsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. brought in $776.6M of revenue over the twelve months to June 30, 2026, up 56.9% from a year earlier. It posted a net loss of $191.6M. In fiscal 2025 capital spending exceeded operating cash flow by $93.9M. At June 30, 2026 it held $319.9M in cash against $188M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Axsome Therapeutics, Inc. does
Axsome Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AXSM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $638.5M | -$183.2M | -$3.68 | -$93.9M |
| 2024 | $385.7M | -$287.2M | -$5.99 | -$128.7M |
| 2023 | $270.6M | -$239.2M | -$5.27 | -$145.7M |
| 2022 | $50M | -$187.1M | -$4.60 | -$117.2M |
| 2021 | n/a | -$130.4M | -$3.47 | -$108.5M |
| 2020 | n/a | -$102.9M | -$2.77 | -$78.5M |
Where AXSM ranks in Health care
Latest SEC filings
What Axsome Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- August 10, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 15, 2026Other event 8-K
- June 9, 2026
- June 9, 2026
- June 3, 2026Other event 8-K
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026
- May 4, 2026
- April 30, 2026Other event 8-K
Insider trades
What the people running Axsome Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | Jacobson Mark L.Chief Operating Officer | Exercised options | 10,000 | $129.5K |
| September 3, 2026 | Jacobson Mark L.Chief Operating Officer | Soldpre-planned (10b5-1) | 10,000 | $2.1M |
Questions about AXSM
What does Axsome Therapeutics, Inc. do?
Axsome Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AXSM.
Is Axsome Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $191.6M on revenue of $776.6M.
How much revenue does Axsome Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Axsome Therapeutics, Inc. reported revenue of $776.6M. That is 56.9% more than a year earlier.
When did Axsome Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Compare AXSM with
Follow AXSM
Get an email when Axsome Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AXSM: get an email when it filesWhere the numbers come from
Financial figures are the values Axsome Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.